person · Reporting owner

Elliott Jeffrey Thomas

Disclosed activity across 5 companies

Tapewire entity: 21236
SEC CIK: 0001689757

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
EXACT SCIENCES CORPEXAS · Entity 56619	Chief Financial Officer	April 30, 2024	May 02, 2024
EXAGEN INC.XGN · Entity 935	Director	June 18, 2020	July 02, 2020
ICON PLCICLR · Entity 3439	Director	August 10, 2026	August 11, 2026
Quanterix CorpQTRX · Entity 6649	Director	August 19, 2026	August 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

EXACT SCIENCES CORP

Report date April 30, 2024 · Filed May 02, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,795	Last balance in matching sequence After 2024-05-01 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2024-04-30 · Grant · Acquired 291 · Balance 11,224 F1: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024. F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Row 2 · 2024-04-30 · Grant · Acquired 707 · Balance 11,931 F3: Represents shares of common stock purchased through Employee Stock Purchase Plan. F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Row 3 · 2024-05-01 · Sale · Disposed 136 · Balance 11,795 F4: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectHeld in 401(k) Plan	1,585	Reported balance Holding disclosure · report date 2024-04-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,585

Filing footnotes · ownership attribution and instrument terms

F1: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024.

F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.

F3: Represents shares of common stock purchased through Employee Stock Purchase Plan.

F4: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units.

EXAGEN INC.

Report date June 18, 2020 · Filed July 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2030-06-17	Direct	9,000	Reported balance After 2020-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-18 · Grant · Acquired 9,000 · Balance 9,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

ICON PLC

Report date August 10, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	1,324	Reported balance After 2026-08-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-10 · Grant · Acquired 1,324 · Balance 1,324 F1: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F2: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.

F2: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.

Quanterix Corp

Report date August 19, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,345	Reported balance After 2026-08-19 transaction · row 1 1 source row Row 1 · 2026-08-19 · Exercise / conversion · Acquired 3,955 · Balance 15,345 F1: Restricted stock units convert into common stock on a one-for-one basis.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	4,075	Reported balance After 2026-08-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-19 · Exercise / conversion · Disposed 3,955 · Balance 4,075 F2: On August 19, 2024, the reporting person was granted 11,985 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On August 19, 2024, the reporting person was granted 11,985 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SERA PROGNOSTICS, INC.

Report date June 04, 2026 · Filed June 04, 2026

Section 16 reporting ended · disclosed 2026-06-04. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2022 Filed Mar 2, 2022 17:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	5,025	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014929 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 25, 2022 Filed Mar 1, 2022 18:44 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantRestricted Stock Units · Derivative	22,802	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014345 · doc4.xml · derivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,802 Underlying: Common Stock · 22,802 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 24, 2022 Filed Feb 25, 2022 18:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	5,897	$70.10	$413,379.70	Disclosure SEC source: 0001209191-22-013326 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,716 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units on February 23, 2022. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 15,906 shares, Mr. Elliott also holds, in the aggregate, an additional 128,478 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 23, 2022 Filed Feb 24, 2022 19:20 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,557	$69.05	$107,510.85	Disclosure SEC source: 0001209191-22-012837 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,866 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 22, 2022. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 9,056 shares, Mr. Elliott also holds, in the aggregate, an additional 128,478 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 23, 2022 Filed Feb 25, 2022 18:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionPerformance Share Units · Derivative	12,747	$0.00	$0.00	Disclosure SEC source: 0001209191-22-013326 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Performance Share Unit represents a right to receive one share of common stock. F5 · derivative.exercise_date: The PSU Award was subject to certain performance-based vesting requirements for the three-year period ending December 31, 2021. F5 · derivative.expiration_date: The PSU Award was subject to certain performance-based vesting requirements for the three-year period ending December 31, 2021. Read SEC document
February 23, 2022 Filed Feb 25, 2022 18:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	12,747	$0.00	$0.00	Disclosure SEC source: 0001209191-22-013326 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon settlement of a performance share unit award (the "PSU Award") on February 23, 2022, which is described further in Footnote 5 to this Form 4. Read SEC document
February 22, 2022 Filed Feb 24, 2022 19:20 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	3,112	$0.00	$0.00	Disclosure SEC source: 0001209191-22-012837 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,337 Underlying: Common Stock · 3,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 22, 2022. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 22, 2022. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. Read SEC document
February 22, 2022 Filed Feb 24, 2022 19:20 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	3,112	$0.00	$0.00	Disclosure SEC source: 0001209191-22-012837 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 15, 2022 Filed Feb 16, 2022 20:14 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,839	$79.55	$146,292.45	Disclosure SEC source: 0001209191-22-010409 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,311 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 14, 2022. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 7,501 shares, Mr. Elliott also holds, in the aggregate, an additional 131,590 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 14, 2022 Filed Feb 16, 2022 20:14 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	3,972	$0.00	$0.00	Disclosure SEC source: 0001209191-22-010409 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,944 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 14, 2022. The restricted stock units vest in four equal annual installments beginning on February 14, 2021. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 14, 2022. The restricted stock units vest in four equal annual installments beginning on February 14, 2021. Read SEC document
February 14, 2022 Filed Feb 16, 2022 20:14 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	3,972	$78.33	$311,126.76	Disclosure SEC source: 0001209191-22-010409 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
January 14, 2022 Filed Jan 19, 2022 16:54 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	3,972	$0.00	$0.00	Disclosure SEC source: 0001209191-22-003760 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,178 F1 · shares: Represents restricted stock units issued to Mr. Elliott in lieu of one-half of his base salary for 2022. The restricted stock units vest in eleven equal monthly installments beginning on February 15, 2022. Each restricted stock unit represents a right to receive one share of Common Stock. F2 · shares: As these restricted stock units vest, Mr. Elliott expects to pay the relevant income taxes out of his base salary or cash on hand, rather than selling shares to cover them. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 5,368 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,248	$114.41	$142,779.19	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 9 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.165 to $114.63, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F10 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,396 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,899	$113.35	$215,257.92	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 8 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.02 to $113.895, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	8,675	$112.39	$974,961.56	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 7 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,353 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	13,853	$111.58	$1,545,706.66	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 6 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,028 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $111.998, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	7,818	$110.64	$864,959.28	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 5 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,881 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $110.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,602	$109.58	$285,117.27	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,699 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,066	$108.54	$115,698.84	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,301 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.23 to $108.73, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,200	$107.54	$129,048.96	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,367 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.16 to $107.92, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,248	$114.41	$142,779.19	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 9 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.165 to $114.63, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F10 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,396 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,899	$113.35	$215,257.92	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 8 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.02 to $113.895, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	8,675	$112.39	$974,961.56	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 7 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,353 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	13,853	$111.58	$1,545,706.66	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 6 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,028 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $111.998, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	7,818	$110.64	$864,959.28	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 5 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,881 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $110.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,602	$109.58	$285,117.27	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,699 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,066	$108.54	$115,698.84	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,301 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.23 to $108.73, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 29, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,200	$107.54	$129,048.96	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,367 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.16 to $107.92, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
April 30, 2021 Filed Aug 2, 2021 16:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	206	$103.22	$21,263.32	Disclosure SEC source: 0001209191-21-049081 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,567 F1 · shares: Represents shares of common stock purchased through Employee Stock Purchase Plan. Read SEC document
April 30, 2021 Filed Aug 3, 2021 13:00 UTC Amendment	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	206	$103.22	$21,263.32	Disclosure SEC source: 0001209191-21-049201 · doc4a.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,567 Read SEC document
March 03, 2021 Filed Mar 5, 2021 16:49 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,632	$135.02	$355,372.64	Disclosure SEC source: 0001209191-21-018262 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,361 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 39,551 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 02, 2021 Filed Mar 3, 2021 20:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,837	$140.31	$257,749.47	Disclosure SEC source: 0001209191-21-017521 · doc4.xml · nonDerivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,993 F3 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F4 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 42,139 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 02, 2021 Filed Mar 3, 2021 20:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,393	$138.42	$331,239.06	Disclosure SEC source: 0001209191-21-017521 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,830 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on March 1, 2021. Read SEC document
March 01, 2021 Filed Mar 2, 2021 18:59 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	6,803	$136.79	$930,582.37	Disclosure SEC source: 0001209191-21-016475 · doc4.xml · nonDerivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,198 F3 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. F4 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 41,344 shares, Mr. Elliott also holds, in the aggregate, an additional 140,587 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 01, 2021 Filed Mar 2, 2021 18:59 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,600	$137.44	$219,904.00	Disclosure SEC source: 0001209191-21-016475 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,001 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 26, 2021. Read SEC document
March 01, 2021 Filed Mar 3, 2021 20:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	5,025	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017521 · doc4.xml · derivative · entry 5 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,025 Underlying: Common Stock · 5,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 27, 2018 that partially vested on March 1, 2021. The restricted stock units vest in four equal annual installments beginning on February 27, 2019. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 27, 2018 that partially vested on March 1, 2021. The restricted stock units vest in four equal annual installments beginning on February 27, 2019. Read SEC document
March 01, 2021 Filed Mar 3, 2021 20:33 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	5,025	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017521 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 26, 2021 Filed Mar 2, 2021 18:59 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	3,437	$0.00	$0.00	Disclosure SEC source: 0001209191-21-016475 · doc4.xml · derivative · entry 5 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,874 Underlying: Common Stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2019 that partially vested on February 26, 2021. The restricted stock units vest in four equal annual installments beginning on February 26, 2020. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2019 that partially vested on February 26, 2021. The restricted stock units vest in four equal annual installments beginning on February 26, 2020. Read SEC document
February 26, 2021 Filed Mar 2, 2021 18:59 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	3,437	$0.00	$0.00	Disclosure SEC source: 0001209191-21-016475 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 24, 2021 Filed Feb 25, 2021 19:24 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	4,449	$136.30	$606,398.70	Disclosure SEC source: 0001209191-21-014494 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,164 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 23, 2021. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 46,310 shares, Mr. Elliott also holds, in the aggregate, an additional 144,024 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 23, 2021 Filed Feb 25, 2021 19:24 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	9,300	$0.00	$0.00	Disclosure SEC source: 0001209191-21-014494 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 23, 2021. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 23, 2021. The restricted stock units vest in four equal annual installments beginning on February 23, 2018. Read SEC document
February 23, 2021 Filed Feb 25, 2021 19:24 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	9,300	$0.00	$0.00	Disclosure SEC source: 0001209191-21-014494 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 19, 2021 Filed Feb 23, 2021 18:41 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantRestricted Stock Units · Derivative	12,449	$0.00	$0.00	Disclosure SEC source: 0001209191-21-013408 · doc4.xml · derivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,449 Underlying: Common Stock · 12,449 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 17, 2021 Filed Feb 18, 2021 19:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,020	$142.66	$288,173.20	Disclosure SEC source: 0001209191-21-012162 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,313 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 16, 2021. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 41,459 shares, Mr. Elliott also holds, in the aggregate, an additional 140,875 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 16, 2021 Filed Feb 18, 2021 19:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	3,972	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012162 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 16, 2021. The restricted stock units vest in four equal annual installments beginning on February 16, 2021. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 16, 2021. The restricted stock units vest in four equal annual installments beginning on February 16, 2021. Read SEC document
February 16, 2021 Filed Feb 18, 2021 19:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	3,972	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012162 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
July 31, 2020 Filed Aug 4, 2020 17:02 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionStock Option (right to buy) · Derivative	6,638	$0.00 Strike: $21.68	$0.00	Disclosure SEC source: 0001209191-20-044729 · doc4.xml · derivative · entry 9 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,362 Underlying: Common Stock · 6,638 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 31, 2020 Filed Aug 4, 2020 17:02 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	400	$97.42	$38,968.00	Disclosure SEC source: 0001209191-20-044729 · doc4.xml · nonDerivative · entry 7 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,361 F2 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.40 to $97.49, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F9 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 39,508 shares, Mr. Elliott also holds, in the aggregate, an additional 144,847 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
July 31, 2020 Filed Aug 4, 2020 17:02 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	5,312	$95.11	$505,224.32	Disclosure SEC source: 0001209191-20-044729 · doc4.xml · nonDerivative · entry 6 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,761 F2 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.89 to $95.65, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document
July 31, 2020 Filed Aug 4, 2020 17:02 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	15,604	$94.38	$1,472,705.52	Disclosure SEC source: 0001209191-20-044729 · doc4.xml · nonDerivative · entry 5 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,073 F2 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.84 to $94.83, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.